Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Biib save search
Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
Published: 2022-06-03 (Crawled : 15:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.16%
H: 3.3%
C: 1.27%
solutions biosimilar positive phase 3
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
Published: 2022-06-01 (Crawled : 12:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.3M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -1.11%
H: 0.11%
C: -0.99%
therapeutics depression phase 3
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
Published: 2022-03-16 (Crawled : 16:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.96%
H: 1.5%
C: 1.28%
aduhelm alzheimer disease phase 3 merge alzheimer’s alzheimer's disease alzheimer's
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.96%
H: 1.5%
C: 1.28%
aduhelm alzheimer disease phase 3 alzheimer’s alzheimer's disease alzheimer's
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints
Published: 2022-02-16 (Crawled : 13:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.3M
|
Health Technology
|
| O: -16.67%
H: 5.38%
C: -0.94%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -0.29%
H: 0.0%
C: -1.01%
therapeutics phase 3
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Published: 2021-10-17 (Crawled : 00:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -2.1%
H: 0.03%
C: -3.47%
results topline phase 3 als
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Published: 2021-09-15 (Crawled : 12:15) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.58%
H: 4.44%
C: 2.67%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.03%
H: 1.15%
C: 0.07%
potential phase 3
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.21%
H: 2.76%
C: 1.42%
multiple sclerosis sclerosis phase 3
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Published: 2021-06-17 (Crawled : 12:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.0%
H: 1.43%
C: -1.99%
phase 3 lupus
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Published: 2021-06-15 (Crawled : 11:00) - globenewswire.com
SAGE | $14.0 8.11% 7.5% 2.3M
|
Health Technology
|
| O: -10.79%
H: 3.81%
C: -9.54%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -0.65%
H: 1.71%
C: -1.84%
positive results phase 3 depression major depressive disorder
Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
Published: 2021-06-01 (Crawled : 12:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: -1.91%
positive results positive results phase 3 biosimilar
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.56%
H: 0.0%
C: -2.38%
rheumatoid arthritis commercialization potential license phase 3 biosimilar
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.